Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Ramucirumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms RamAtezo-1
- 07 Jun 2019 Status changed from not yet recruiting to recruiting.
- 24 Apr 2019 Planned End Date changed from 30 Jun 2023 to 31 Aug 2023.
- 24 Apr 2019 Planned primary completion date changed from 30 Jun 2021 to 31 Aug 2021.